| abstract |
The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents -C(=O)-; -O-C(=O)-; -C(=O)-C(=O)-; -NR-C(=O)-; -Z-C(O)-; -Z-NR-C(=O)-; -C(=O)-Z-; -NR-C(=O)-Z-; -S(=O)p-; -C(=S)-; -NR-C(=S)-; -Z-C(=S)-; -Z-NR-C(=S)-; -C(=S)-Z1-; -NR-C(=S)-Z-; Y represents NR-C(=0)- Z-; -NR-C(=0)-Z-NR-; -NR-C(=0)-Z-NR-C(=0)-; -NR-C(=0)-Z-NR-C(=0)- O-; -NR-C(=0)-Z-0-; -NR-C(=0)-Z-0-C(=0)-; -NR-C(=0)-Z-C(=0)-; -NR-C(=0)-Z-C(=0)-0-; -NR-C(=0)-0-Z-C(=0)-; -NR-C(=0)-0-Z-C(=0)-0-; -NR-C(=O)-O-Z-O-C(=O)-; -NR-C(=O)-Z-C(=O)-NR-; -NR-C(=O)-Z-NR- C(=0)-NR-; -C(=O)-Z-; -C(=O)-Z-O-; -C(=0)-NR-Z-; -C(=0)-NR-Z-0-; -C(=0)-NR-Z-C(=0)-0-; -C(=0)-NR-Z-0-C(=0)-; -C(=0)-NR-0-Z-; -C(=O)- NR-Z-NR-; -C(=0)-NR-Z-NR-C(=0)-; -C(=0)-NR-Z-NR-C(=0)-0-; R represents Calkyl optionally substituted with cyano, Calkyloxy, Calkyl-oxyCalkyloxy, CCy cloalkyl or aryl; Calkenyl; Calkynyl; Ccycloalkyl; adamantanyl; aryl; arylCalkyl; Het; or HetCalkyl; provided that when Y represents -NR-C(=O)-Z-; -NR-C(=0)-Z-NR; -NR-C(=O)-Z-C(=O)- NR-; -C(=O)-Z-; -NR-C(=0)-Z-NR-C(=0)-NR-; -C(=O)-NR-Z-; -C(=O)-NR- O-Z-; or -C(=0)-NR-Z-NR-; then R may also represent hydrogen; R represents hydrogen, Calkyl, Calkenyl or R; provided that if X represents -O-C(=O)-, then R represents R; and provided that is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds. |